500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
News | 2024-04-24
Clinical phase 1 a success
The results from Dicot's phase 1 study have arrived, clearly showing that LIB-01 has a very good safety profile. Additionally, an effect signal emerged, resulting in improved erectile function among participants.
Read More >Dicot - the potency drug of tomorrow
News | 2023-11-24
Great interest for Dicot at North America's major sexual medicine congress
Dicot's CSO participated alongside Professor François Giuliano and sexual medicine expert Dr. Harin Padma-Nathan and experienced a lot of attention for our work.
Read More >
The global market for treating sexual dysfunctions is annually worth around 7 billion USD and will increase due tu underlying causes such as growing number of elderly
Today's potency drugs were launched over twentyfive years ago and have limitations
Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped
Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 can have an effect lasting at least seven days
Sexual medicine experts states that there is a great need for new potency drugs
In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma
The ambition with LIB-01
- Longer duration
- Effective for everyone
- Minimal side-effects
